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Abstract
Chronic heart failure (CHF) is a common condition with a poor prognosis. It is associated
with poor exercise tolerance and debilitating symptoms. These symptoms appear to be
associated with pathophysiological changes that occur systemically in the patient with CHF.
Exercise training in carefully selected patients has been shown to be safe and to improve
exercise capacity. Many of the pathophysiological abnormalities of CHF are improved by
training. Some studies have suggested a possible improvement in morbidity and mortality
with training. This review analyzes the controlled clinical trials of exercise training in CHF
published to date.
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Introduction
Chronic heart failure is a common condition with a poor
prognosis. It is associated with debilitating limiting symp-
toms even with optimal modern medical management.
One of the most prominent symptoms of CHF is severe
exercise intolerance with marked fatigue and dyspnea at
low exercise workloads.
The severity of symptomatic exercise limitation varies
between patients with CHF and appears to be unrelated to
the extent of left ventricular systolic dysfunction at rest.
Peripheral changes commonly occur in patients with CHF
and have been implicated in the development of symptoms
in this condition. The reason for fatigue in CHF has been
more readily attributed to persistent vasoconstrictor drive,
endothelial dysfunction, and a wide range of structural and
functional abnormalities of skeletal muscle than to ventricu-
lar dysfunction per se [1]. Similarly, dyspnea appears to be
more closely related to enhanced ventilatory effort than pul-
monary congestion in most well-treated non-edematous
patients [2]. This may be related to augmented reflex
control systems, such as the arterial chemoreflexes and the
muscle ergoreflexes (metaboreflexes) [3,4].
Interest has been shown in the possibility that some forms
of exercise therapy, either localized or systemic, could
benefit the peripheral manifestations of CHF and thereby
modify the symptoms of patients with CHF. Recently it has
even been suggested that regular training could have ben-
eficial effects on disease progression and survival. This
review looks at the controlled clinical trial evidence for the
role of exercise therapy in the management of patients
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dwith CHF. It will concentrate on generalized exercise train-
ing programs and will not look at selective respiratory
muscle training.
The beneficial effects of exercise training in cardiac
patients without symptomatic heart failure have been well
described and will not be reviewed here. This review
focuses on the evidence for training as a therapeutic
option in patients with stable symptomatic CHF and refers
specifically to studies on post-infarct left ventricular dys-
function or selective muscle training where necessary.
Exercise training in chronic heart failure
Participation in an exercise program was historically consid-
ered to be ill-advised for patients with significant left ventric-
ular impairment. Until the late 1980s, avoidance of physical
exercise was the standard recommendation for all patients
suffering from heart failure. This was initially challenged by
uncontrolled studies that showed that selected patients
with significantly impaired left ventricular function could
increase their exercise tolerance after a period of exercise
training [5,6,7]. There was no detectable deterioration in left
ventricular function in patients included in these studies.
It was not until the end of the 1980s that reports were
published showing that physical training could increase
exercise capacity in patients with CHF. Sullivan and col-
leagues [8,9] found that patients with severe left ventricu-
lar dysfunction, some of whom had previously suffered
heart failure, improved their maximal exercise performance
after a prolonged regime of physical training. They demon-
strated an increased blood flow to exercising muscle and
an increased ability of skeletal muscle to extract oxygen
from the nutritive blood flow. Ventilatory function was also
improved, with a reduction in the respiratory exchange
ratio at sub-maximal exercise and a delay in the anaerobic
threshold. These authors showed no improvement in exer-
cise cardiac output, so the training-induced benefits
appeared to be mainly caused by peripheral adaptations.
The beneficial effects of training were confirmed in a con-
trolled cross-over trial in 11 patients with stable class II-III
CHF [10]. These carefully selected patients could exercise
without serious ventricular arrhythmias and had no other
medical condition that limited their exercise tolerance. After
baseline evaluation and familiarization with laboratory proce-
dures, all patients completed 8 weeks of exercise training
and 8 weeks without exercise in a randomized cross-over
study. The training regime produced a 20–25% increase in
exercise tolerance and peak oxygen consumption. There was
also a significant reduction in questionnaire-rated symptoms
attributable to heart failure and a coincident increase in the
extent and ease of performing daily activities. Since these
early reports, numerous trials of similar design have con-
firmed these benefits and have shown many additional
advantages of training in patients with heart failure. The
randomized trials of parallel group design are summarized in
Table 1 and those of cross-over design are in Table 2.
Training for heart failure: development of an idea
The earliest reports of training patients with significant left
ventricular impairment were case reports or small series.
The first report of exercise training of patients with heart
failure was in 1987, in Russia [11]. This study compared the
effects of exercise training with no exercise in post-myocar-
dial infarction patients who showed clinical signs of heart
failure. The training continued for 11 months and included
exercise therapy, cycle ergometry and walking. The patients
who exercised showed a considerable increase in physical
working capacity, a more favorable hemodynamic response
to stress, a higher stroke index, a reduced heart rate incre-
ment and a greater reduction in systemic peripheral resis-
tance compared with the control patients.
Further physiological investigation of the training-induced
improvements in exercise capacity was undertaken by Sul-
livan and colleagues [8,9]. This was closely followed in the
early 1990s by the first randomized controlled trials of
training in patients with chronic stable heart failure
[10,12], which showed an increase in exercise capacity
and improved symptomatic status.
In the rest of the 1990s, an increasing number of larger
and better designed studies in patients with heart failure
demonstrated a consistent increase in exercise capacity
and a bewildering array of physiological benefits with exer-
cise training. A summary of trials performed by a collabora-
tive European group [13] and an overview of all trials
published up to 1998 [14] have shown a consistent
15–20% increase in exercise capacity in a broad range of
patients with heart failure. The beneficial effects of training
have included improvements in hemodynamic responses,
myocardial perfusion, diastolic function, skeletal muscle
function and histological and biochemical responses, ven-
tilatory control, peripheral vascular and endothelial func-
tion and neurohormonal and autonomic function.
Global exercise capacity was improved even with only low
intensity training by relatively small muscle groups, which
shows the primary importance of peripheral training mech-
anisms in even severe heart failure [15]. Although the
majority of these training effects are likely to be beneficial
for a patient with CHF, none of the trials to date has been
designed specifically to address the question of prognosis
or alteration in disease progression. The largest reported
controlled trial [16] included almost 100 patients and
showed a statistically significant improvement in survival
and a statistically significant reduction in hospital readmis-
sions for heart failure. The results of this study, however,
must be regarded as an exciting possibility of benefit
rather than proof. A sufficiently powered trial is required to
evaluate the proposal that training may improve survival.
Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 CoatsUnanswered questions
Although there are many reports of training, few have
prospectively compared the elements of the training
program. Important points that still need to be considered
include the optimal frequency and intensity of training, the
necessary duration for training effects and how long these
effects last after cessation of a formal program. Other
points that need to be addressed in future controlled trials
include details of the most appropriate selection of
patients, the elements of the training program and possi-
ble interactions with modern heart failure medications.
Although cardiovascular medicine has greatly improved in
the last decade as a result of randomized controlled trials
of effective treatments, this oldest of physical therapies
remains extremely difficult to evaluate. This is at least
partly because our modern system of funding trials is firmly
in favor of commercial patentable treatments. A program
of government support for randomized non-commercial
treatment trials is needed if these important questions and
considerations are to receive a timely answer.
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